1. Home
  2. GBIO vs BODI Comparison

GBIO vs BODI Comparison

Compare GBIO & BODI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • BODI
  • Stock Information
  • Founded
  • GBIO 2016
  • BODI 1998
  • Country
  • GBIO United States
  • BODI United States
  • Employees
  • GBIO N/A
  • BODI N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • BODI Industrial Machinery/Components
  • Sector
  • GBIO Health Care
  • BODI Industrials
  • Exchange
  • GBIO Nasdaq
  • BODI Nasdaq
  • Market Cap
  • GBIO 29.2M
  • BODI 25.4M
  • IPO Year
  • GBIO 2020
  • BODI N/A
  • Fundamental
  • Price
  • GBIO $0.56
  • BODI $4.06
  • Analyst Decision
  • GBIO Strong Buy
  • BODI Strong Buy
  • Analyst Count
  • GBIO 4
  • BODI 3
  • Target Price
  • GBIO $7.33
  • BODI $10.67
  • AVG Volume (30 Days)
  • GBIO 1.7M
  • BODI 18.9K
  • Earning Date
  • GBIO 08-06-2025
  • BODI 08-05-2025
  • Dividend Yield
  • GBIO N/A
  • BODI N/A
  • EPS Growth
  • GBIO N/A
  • BODI N/A
  • EPS
  • GBIO N/A
  • BODI N/A
  • Revenue
  • GBIO $24,556,000.00
  • BODI $371,113,000.00
  • Revenue This Year
  • GBIO N/A
  • BODI N/A
  • Revenue Next Year
  • GBIO N/A
  • BODI N/A
  • P/E Ratio
  • GBIO N/A
  • BODI N/A
  • Revenue Growth
  • GBIO 146.47
  • BODI N/A
  • 52 Week Low
  • GBIO $0.30
  • BODI $3.38
  • 52 Week High
  • GBIO $3.65
  • BODI $8.71
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 67.17
  • BODI 51.85
  • Support Level
  • GBIO $0.32
  • BODI $3.81
  • Resistance Level
  • GBIO $0.36
  • BODI $4.15
  • Average True Range (ATR)
  • GBIO 0.03
  • BODI 0.28
  • MACD
  • GBIO 0.02
  • BODI 0.02
  • Stochastic Oscillator
  • GBIO 94.21
  • BODI 53.75

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About BODI The Beachbody Company Inc. Class A Common Stock

The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.

Share on Social Networks: